We next examined the effects of ruxolitinib co-exposure upon TSLPRCART activity against CD19+ CRLF2-rearranged Ph-like B-ALL MUTZ5 cells in vitro. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.